Markus Bredel, MD, PhD

Dr. Bredel is Chairman and Sylvester Professor of Radiation Oncology of the Department of Radiation Oncology at the University of Miami’s Miller School of Medicine. Dr. Bredel is a board-certified, German-American physician-scientist who focuses clinically and scientifically on CNS tumors and functional disorders of the brain. Dr. Bredel previously held academic faculty positions at Stanford University, Northwestern University, the University of Freiburg, and UAB.

An NIH R01-funded physician-scientist, Dr. Bredel’s nationally acclaimed work has contributed greatly to the understanding of brain tumor genetics. He served as the Billy Grey Chair of Research of the NBTS. The PI on high-impact studies published in esteemed journals, including NEJM, JAMA, The Lancet Oncology, JCI, the JCO, and Cell Reports Medicine, his research team’s characterization of a novel tumor suppressor gene in brain cancer was named one of the top clinical cancer research advances of the year by ASCO. Dr. Bredel served on The Lancet Oncology editorial board. He chaired the Central Nervous System Tumors Program Subcommittee of ASCO.

Dr. Bredel has unique clinical expertise in CNS tumors and a particular interest in advanced radiosurgery for brain metastases and movement disorders. He is part of the CNS Radiation Oncology group that led the development of HyperArc. He has developed an advanced SRS program for movement disorders. The FDA’s 510(K) approval of the Varian Edge SRS platform for the treatment of essential tremor stemmed from a clinical trial for which he was PI. Dr. Bredel also performed the world’s first frameless radiosurgical pallidotomy for dystonia.

Disclosures:

• Employment: University of Miami:Chairman and Sylvester Professor:Employee
• Compensation: Varian Medical Systems: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant, Education Meeting Faculty, Research Grants, Research Funding, Research Salary Support,Speaker's Bureau, Grant Research Funding, Honoraria, Travel Expenses, Salary Support, Compensation Payment-End Date: To Present
• Ownership: none
• Leadership: none